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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Induction of IL-4R–dependent microRNAs identifies PI3K/Akt signaling as
essential for IL-4–driven murine macrophage proliferation in vivo
Dominik Ru¨ckerl,1 Stephen J. Jenkins,1 Nouf N. Laqtom,1,2 Iain J. Gallagher,3 Tara E. Sutherland,1 Sheelagh Duncan,1
Amy H. Buck,1 and Judith E. Allen1
1Institute of Immunology and Infection Research, Centre for Immunity, Infection and Evolution, School of Biological Sciences, University of Edinburgh,
Edinburgh, United Kingdom; 2Department of Biology, King Abdulaziz University, Jeddah, Saudi Arabia; and 3Medical Research Council Centre for Regenerative
Medicine, University of Edinburgh, Edinburgh, United Kingdom
Macrophage (M) activation must be
tightly controlled to preclude overzeal-
ous responses that cause self-damage.
MicroRNAs promote classical M activa-
tion by blocking antiinflammatory signals
and transcription factors but also can
prevent excessive TLR signaling. In con-
trast, the microRNA profile associated
with alternatively activated M and their
role in regulating wound healing or anti-
helminthic responses has not been de-
scribed. By using an in vivo model of
alternative activation in which adult Bru-
gia malayi nematodes are implanted sur-
gically in the peritoneal cavity of mice, we
identified differential expression of miR-
125b-5p, miR-146a-5p, miR-199b-5p, and
miR-378-3p in helminth-induced M. In
vitro experiments demonstrated that miR-
378-3p was specifically induced by IL-4
and revealed the IL-4–receptor/PI3K/Akt-
signaling pathway as a target. Chemical
inhibition of this pathway showed that
intact Akt signaling is an important en-
hancement factor for alternative activa-
tion in vitro and in vivo and is essential
for IL-4–driven M proliferation in vivo.
Thus, identification of miR-378-3p as an
IL-4R–induced microRNA led to the dis-
covery that Akt regulates the newly dis-
covered mechanism of IL-4–driven macro-
phage proliferation. Together, the data
suggest that negative regulation of Akt
signaling via microRNAs might play a
central role in limiting M expansion and
alternative activation during type 2 inflam-
matory settings. (Blood. 2012;120(11):
2307-2316)
Introduction
Macrophages (M) are involved centrally in recognizing and
containing pathogens. Subsequently, they ensure the efficient
induction and upkeep of a protective adaptive immune response.
M also help to limit the ensuing immune reaction as well as clear
apoptotic cells and other debris.1 The adaption of M to these
diverse roles is reflected in the multitude of activation phenotypes
that have been described.2 Classical (or M1) and IL-4R–driven
alternative (or M2) activation represent the 2 most divergent
phenotypes, with the former thought to be proinflammatory and
important for the clearance of microbial pathogens, whereas the
latter are predominantly found during helminth infections and are
associated with wound healing and immunosuppression.3-6 In
either case, M activation must be closely controlled because
excessive activation can lead to tissue destruction or fibrosis,
respectively.6,7 Control is achieved by external signals, including
cytokines (eg, IL-10, IL-278,9) and hormones (eg, glucocortico-
ids10) but also by M-intrinsic mechanisms. For example, classi-
cally activated M become unresponsive to secondary stimulation
with lipopolysaccharide (LPS) as the result, at least in part, of the
induction of negative feedback loops blocking or limiting activat-
ing signaling cascades.11 The possibility that microRNAs may
mediate such feedback mechanisms has recently attracted consider-
able interest.11
MicroRNAs (miRNA) are short (18-24 nt), noncoding RNAs
that influence the translation of specific genes by binding to the
3-untranslated region (3UTR) of the target messenger RNAs
(mRNAs). The interaction between a miRNA and mRNA generally
results in destabilization of the mRNA and repression of transla-
tion.12 In M, miRNAs have so far been mainly studied during
classical activation, where several miRNAs have been found to be
differentially regulated (reviewed in O’Neill et al13). miR-125b-5p
initially is down-regulated by LPS/TNF-induced Akt signaling to
allow efficient TNF production14,15 but is induced during later
stages, where it acts to limit further TNF production.16 Similarly
miR-146a-5p is up-regulated upon stimulation with LPS and targets
the MAPK-signaling pathway of TLRs, specifically IRAK1 and
TRAF6.17 Thus, these miRNAs are part of feedback loops that
prevent excessive M activation and limit potentially harmful
proinflammatory responses. Another M1-associated miRNA, miR-
155, can suppress M2 activation by targeting the IL-13 receptor,18
suggesting that miRNAs also are involved in shaping the M1/M2
balance. Furthermore, miRNAs have been shown to control
cellular proliferation,19 which has potential relevance to M2 M
activation because of the recent discovery that M expansion can
occur by IL-4–driven local proliferation rather than recruitment
from the blood.20
However, the miRNA-profile associated with alternative activa-
tion of M has yet to be described. We therefore aimed to identify
miRNAs differentially expressed in an in vivo model of alternative
activation and dissect their functional roles. Microarray analysis of
M elicited by exposure to the nematode Brugia malayi5,21
identified miR-378-3p as one of the most robustly regulated
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miRNAs in this Th2 infection context, and experiments in vitro
demonstrated that miR-378-3p was induced upon stimulation with
IL-4. In silico analysis and miRNA manipulation studies identified
potential miR-378-3p targets in the PI3K/Akt-signaling cascade,
downstream of the IL-4 receptor. The finding that Akt is a target of
miR-378-3p led us to test the consequences of Akt inhibition,
revealing this signaling pathway as a critical component of
IL-4–driven M proliferation and alternative activation in vivo.
Thus, it is likely that miRNAs are a general mechanism for limiting
M activation in both alternative and classical activation settings.
Methods
Mice and infection
Wild-type (WT; BALB/c or C57BL/6) and IL-4 receptor-–deficient
(IL-4R/) mice on a BALB/c background were bred in house. Mice were
6-10 weeks of age at the start of each experiment, and all work was
performed in accordance with the United Kingdom Animals (Scientific
Procedures) Act of 1986. Adult B malayi parasites were isolated from the
peritoneal cavity of infected jirds purchased from TRS Laboratories or
maintained in house. Infections were carried out as described previously.21
A detailed description and additional information can be found in supple-
mental Methods, available on the Blood Web site; see the Supplemental
Materials link at the top of the online article.
M isolation and purification
Peritoneal exudate cells (PECs) were seeded at 5  106 cells per well to
6-well cell-culture plates (NUNC) in RPMI, 5% FCS, 2mM L-glutamine,
0.25 U/mL penicillin, and 100 mg/mL streptomycin. After 4 hours incuba-
tion at 37°C/5% CO2, nonadherent cells were washed off, and the adherent
cells detached with a rubber policeman. Detached cells were  80% pure
M as assessed by fluorescence-activated cell sorting (FACS) analysis of
their F4/80 and CD11b surface expression. In some experiments as
indicated, peritoneal M were purified with FACS on a FACSAria cell
sorter (BD Biosciences) according to their expression of surface molecules
(F4/80, SiglecF, CD11b, CD11c, B220, CD3; all antibodies
purchased from BioLegend or eBioscience) reaching purities of 90%.
Cell-culture experiments
For in vitro experiments, thioglycollate (Thio)-elicited PECs were seeded to
24-well plates at 1  106 cells per well in complete RPMI. After 4 hours’
incubation, nonadherent cells were washed off, and murine recombinant
IL-4 (rIL-4, 20ng/mL, Peprotech), recombinant M-CSF (rM-CSF; 20 ng/
mL; Peprotech), LPS (100 ng/mL; Escherichia coli 0111:B4; Sigma-
Aldrich), and recombinant IFN- (rIFN; 20 ng/mL; Peprotech) or medium
alone were added and incubated for various periods of time as indicated in
the “Results.” For triciribine (1,5-dihydro-5-methyl-1-	-D-ribofuranosyl-
1,2,5,6,8-pentaazaacenaphthylen-3-amine; Cayman Europe) treatment, cells
were pretreated for 1 hour (see Figure 4 for concentrations) before
stimulation. Subsequently, nonadherent cells were washed off and the
remaining cells lysed in 700 
L of Qiazol.
miRNA microarray
The miRCURY miRNA probe set version 8.1 (Exiqon) was printed onto
Codelink slides (GE Healthcare) in triplicate per array. Arrays were
spot-checked with random hexamer-labeled RNAs. For experiments in this
report, RNA (1 
g) was labeled by using the Hy3 power labeling kit
(Exiqon), and hybridization and washing were carried out by following the
manufacturer’s instructions.
Array analysis was carried out with a comparative strategy to identify
robustly regulated miRNAs. The background subtracted data were quantile
normalized, and the probes recognizing murine miRNA were selected to
minimize the multiple testing problem. Medians were calculated for each
miRNA per group (n  4) and expression compared by t test (WT vs
IL-4R/ and WT vs Thio). The regulated miRNAs in each comparison
were then selected on the basis of those with 2 or more significantly
regulated probes and a log2 median intensity on the array greater than the
50th percentile. Our second analysis strategy used the limma suite22 in
bioconductor.23 A linear model was fitted to each probe across all 4 groups
and regulated miRNAs extracted by contrast. Similarly to our analysis of
medians, we selected miRNAs as regulated if 2 or more probes for the
miRNA had significant uncorrected P values and the median was greater
than the 50th percentile. The lists from each analysis were then examined
and overlapping miRNAs chosen for follow-up analysis. Microarray data
have been deposited to NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession no. GSE35047 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc GSE35047).
Dual-luciferase reporter assay
Whole 3UTRs of target genes (ie, Akt1, Grb2) were cloned into the
psiCHECK-2 vector (Promega) immediately downstream of the Renilla
luciferase gene. Mutations in the 3UTR of Akt1 or Grb2 were generated
with the QuikChange Lightning Multi Site-Directed Mutagenesis Kit
(Stratagene), resulting in altered binding sites for miR-378-3p (AGUC-
CAG3 AGUGGAG). NIH-3T3 fibroblasts were cotransfected with 200 ng
of the psiCHECK-2 constructs and 2.5 pmol of synthetic miR-378-3p
precursor (hsa-miR-378 premiR; Applied Biosystems) or scrambled miRNA
control (premiR neg. control no. 1; Applied Biosystems) using Lipo-
fectamine 2000 (Invitrogen). At 48 hours after transfection, relative lumines-
cence was measured with the Dual-Luciferase Reporter Assay System
(Promega) on a LumiStar luminometer (BMG Labtech) following the
manufacturer’s instructions. Resulting luminescence values were used to
generate ratios of Renilla to firefly luciferase activity and are depicted as
fold change compared with a no-RNA transfected control for each
construct.
Affymetrix messenger RNA array and data analysis
To determine genes potentially regulated by miR-378-3p, NIH-3T3 cells
were reverse-transfected with a miR-378-3p mimic or inhibitor (25nM) and
compared with control-transfected RNA-induced silencing complex (RISC)–free
siRNA cells. A total of 300 ng of total RNA was converted to cDNA with
the GeneChip WT cDNA Synthesis and Amplification Kit (Affymetrix) and
hybridized to Affymetrix GeneChip Mouse Gene 1.0 ST Array according to
the manufacturer’s instructions. For the bioinformatic analysis, Partek
Genomics Suite Version 6.5 software (Partek Inc) was used to assess the
GeneChip quality control and perform gene expression analysis using
Affymetrix metafiles. Data from 9 chips met the quality control require-
ments; thereby, all were included.
The RMA method was used to normalize and summarize the intensity
levels of all 28 853 probes.24 On the basis of the (log 2 value) of negative
control probes of each chip, the background fluorescence was calculated in
StatPlus statistical tool pack software (AnalystSoft) and then used to
statistically eliminate the microarray’s background noise generating a list of
12 665 probes. We used Partek software to compute the fold change and
statistical significance (false discovery rate–adjusted P value) using 1-way
ANOVA test. Microarray data have been deposited to NCBI’s Gene
Expression Omnibus and are accessible through GEO Series accession
no. GSE34873 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc
GSE34873).
In vivo IL-4 complex treatment
M proliferation in vivo was stimulated by intraperitoneal injection of
5 
g of rIL-4 complexed to 25 
g of anti–IL-4 antibody (IL-4c; clone:
11B11; molar ratio 2:1).20 Where indicated, mice were pretreated intraperi-
toneally with triciribine (1 mg/kg) 1 hour before injection of IL-4c. At
21 hours after IL-4c injection, mice received 100 
L of BrdU (10 mg/mL;
Sigma-Aldrich) subcutaneously, and PECs were harvested 3 hours later.
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M transfection experiments
RAW264.7 cells were stained with 5
M of Vybrant CFDA SE cell tracer
(Invitrogen) followed by reverse transfection with a miR-378-3p mimic or
inhibitor (25nM) as described previously and analyzed for cellular expan-
sion after 24 hours and 48 hours. At 4 hours before the end of the
incubation, 100 
L of alamarBlue was added to the culture. Cell prolifera-
tion was analyzed by measuring alamarBlue conversion in a FluoStar
(BMG Labtech) fluorescence plate reader and Vybrant CFDA SE dilution
by FACS analysis. Data were pooled from 3 experiments and are presented
as percent of control to account for inter-experimental changes in staining
intensity.
Statistical analysis
Statistical analysis was performed with JMP statistical analysis software
(JMP 8.0.1; SAS Institute Inc). Differences between groups were deter-
mined by ANOVA followed by a Tukey-Kramer HSD multiple comparison
test. In some cases, data were log-transformed to achieve normal distribu-
tion as determined by optical examination of residuals, or where this was
not possible, a Kruskal-Wallis test was used. Differences were considered
statistically significant for P .05.
Results
To identify miRNAs differentially regulated in alternatively acti-
vated M in vivo, we performed a miRNA array screen on
peritoneal M isolated from mice surgically implanted with the
parasitic nematode B malayi. As described previously, B malayi
implant results in a very strongly Th2-biased immune response and
induces the accumulation of alternatively activated M at the site
of implantation.5 For comparison, we used IL-4R–deficient
(IL-4R/) animals whose M fail to express alternative activa-
tion markers in this model.25 Additional WT mice underwent sham
surgery and were injected with Thio 3 days before necropsy to
generate inflammatory M not associated with helminth infection.
A 2-way comparison of WT nematode-elicited M (NeM) with
Thio-elicited M (Thio-M) or IL-4R/ NeM allowed us to
identify infection-dependent and IL-4R–dependent miRNAs,
respectively. At 3 weeks after implantation, Mwere isolated from
the peritoneal cavity by adherence to cell-culture plates and total
RNA extracted. The expression levels of 648 unique human and
mouse miRNAs in their mature form were determined by use of the
Exiqon miRCury 8.1 array platform. Bioinformatic analysis (see
“miRNA microarray” for details) revealed differential expression
of 19 miRNAs in WT-NeM compared with either Thio-M or
IL-4R/ NeM (supplemental Table 2).
We then chose to validate expression levels of the 10 most
differentially regulated miRNAs (ie, greatest fold change) identi-
fied in the array. A proportion of the originally isolated RNA was
subjected to quantitative RT-PCR (qRT-PCR), with further analysis
in 2 subsequent experiments using FACS-sorted M ( 90%
F4/80CD11b). These experiments confirmed significant differen-
tial expression of 9 of these 10 miRNAs but also revealed that only
4 of these were differentially regulated in both comparisons (WT
NeM vs WT Thio-M and vs IL-4R/ NeM) and therefore
specific for alternatively activated M (Table 1 and Figure 1A).
miR-125b-5p, miR-199b-5p, and miR-378-3p were found to be
significantly up-regulated in vivo, whereas miR-146a-5p showed a
tendency toward an IL-4R–dependent downmodulation (Figure
1A). This tendency in miR-146a-5p expression was statistically
significant (P  .0022) when all 3 experiments were combined. To
confirm the activation state of the isolated M, expression of the
alternative activation marker chitinase 3-like 3 (Chi3l3/Ym1) was
measured and, as expected, found to be exclusively up-regulated in
WT NeM but not in IL-4R/ M (Figure 1B).
It was possible that the changes we observed were the result of
secondary (IL-4R–dependent) events occurring in vivo and not
because of direct M activation via IL-4/13. Thus, we tested the
expression of miR125b-5p, miR-146a-5p, miR-199b-5p, and miR-
378-3p in Thio-M stimulated in vitro with rIL-4 or LPS and
rIFN (Figure 1C). qRT-PCR revealed significant up-regulation of
miR-125b-5p and miR-378-3p after treatment with IL-4 but not
after LPS/IFN-stimulation, confirming the association of these
miRNAs with the alternative activation phenotype. In contrast,
miR-199b-5p was not altered by IL-4 or LPS/IFN treatment,
indicating that the observed up-regulation in vivo is not because of
direct effects of IL-4R–signaling on M. miR-146a-5p has previ-
ously been found to be highly up-regulated in classically activated
M17 and was consequently specifically induced by LPS/IFN
stimulation, but no change in expression could be detected by IL-4
stimulation in vitro at this time point (Figure 1C). Successful and
specific induction of alternative activation under these conditions
was confirmed by Chi3l3-expression (Figure 1D).
miR-125b expression in M has previously been demonstrated
to be modulated by factors other than IL-4.15,16 We selected
miR-378-3p for further investigation into its potential to regulate
alternative activation of M because it appeared to be the most
specific for IL-4R–mediated signals. Furthermore, miR-378-3p
was of particular interest because it is encoded in an intronic region
of the peroxisome proliferative–activated receptor, gamma, coacti-
vator 1 	 gene (Ppargc1b),26 which has previously been shown to
be associated with the alternative activation phenotype.27
To evaluate whether up-regulation of miR-378-3p was a
prerequisite for alternative M activation or a consequence
thereof, we performed in vitro time-course experiments of IL-4
stimulation (Figure 2) in which Thio-M were incubated with
murine rIL-4 for 1, 4, 16, 28, and 45 hours. Cells were subse-
quently analyzed for mRNA and miRNA expression with qRT-
PCR. Significantly increased levels of Chi3l3 expression were
detectable as early as 4 hours after treatment of M with IL-4 and
continued to increase until the end of the experiment. In contrast,
miR-378-3p was not significantly up-regulated until 16 hours after
the addition of IL-4 but remained elevated thereafter. Notably,
classical activation of M via the use of LPS/IFN did not result in
the up-regulation of Chi3l3 or miR-378-3p at any time point but
potently induced expression of inducible nitric oxide synthase
2 (Nos2) and miR-146a-5p as described previously.17,28 Interest-
ingly, in line with our in vivo data (Figure 1A), miR-146a-5p was
Table 1. Log2-fold change of significantly differentially expressed
microRNAs as assessed by microRNA array or qRT-PCR
microRNA-ID
BALB/c NeM vs
BALB/c ThioM
BALB/c NeM vs
IL-4R/ NeM
Array qRT-PCR Array qRT-PCR
miR-18a-5p 1.31 1.01 – –
miR-125b-5p – 2.11 1.91 4.90
miR-146a-5p 1.46 1.47 – 1.47
miR-150-5p – – 1.97 2.15
miR-199b-5p – 3.49 2.04 4.59
miR-221-3p 1.53 2.11 – –
miR-222-3p 1.27 2.11 – –
miR-342-3p 1.51 1.81 – –
miR-378-3p 2.10 2.42 2.28 2.14
miR-689 – – 2.56 –
– indicates not significant.
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significantly reduced after IL-4 stimulation at very late time points
(45 hours) but not at 24 hours. This finding might explain why we
were unable to detect a direct effect of IL-4 on miR-146a-5p
expression in the previous in vitro experiments measured at
16 hours after treatment (Figure 1C).
To examine cellular genes that respond to changes in miR-
378-3p expression, we used a murine fibroblast cell line that
expresses miR-378-3p and supports miRNA overexpression and
inhibition analysis, as described.29 NIH-3T3 fibroblasts were
transfected with either miR-378-3p–mimics or inhibitors and
resulting changes in gene-expression analyzed with an Affymetrix-
mRNA array. We were able to identify 491 significantly differen-
tially expressed genes (false discovery rate; P  .05) with more
than 1.4-fold change in either of the 2 conditions compared with a
negative-control. Pathway enrichment analysis of these differen-
tially expressed genes by DAVID Bioinformatics Resources for
gene annotation and KEGG pathway analysis (http://david.abcc.n-
cifcrf.gov/tools.jsp) revealed the Jak-STAT signaling pathway as
significantly over-represented (EASE-score P  .05).
More specifically, in conjunction with the online prediction
software TargetScan (TargetScanMouse; Release 5.1:April2009;
http://www.targetscan.org) several potential target-genes within the
Figure 1. Validation of differential expression of
miRNAs in AAM in vivo and in vitro. (A) Peritoneal
M were isolated from Thio-injected BALB/c mice or
from B malayi–infected BALB/c (WT) or IL-4R/ (/)
mice and expression of the indicated miRNAs assessed
by qRT-PCR. Each data point shown reflects data from
individual mice. (B) Chi3l3 expression in the cells isolated
in panel A. (C) Thio-elicited, adherence-purified M were
incubated with rIL-4 (IL-4), LPS/IFN (L/I), or without
stimulus () for 16 hours and analyzed as in panel A.
(D) Chi3l3 expression in the cells isolated in panel C. One
of 3 separate experiments shown. *P  .05; **P  .01;
***P  .001; n.s. indicates not significant.
Figure 2. Kinetics of miR-378-3p induction during in
vitro alternative activation. Thio-elicited, adherence-
purified M were incubated with rIL-4 (black squares),
LPS and rIFN (gray triangles), or with medium alone
(open squares) for the indicated time and analyzed for
miRNA and mRNA expression. Statistics indicate differ-
ences between rIL-4–treated samples and media con-
trols. **P  .01; ***P  .001. Each data point represents
mean and SEM of 3 individual animals. One of 2 separate
experiments shown.
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IL-4R/PI3K/Akt–signaling cascade could be identified. Figure
3A illustrates the components of the IL-4R pathway that were
predicted by TargetScan (yellow) and differentially expressed in
transfected fibroblasts (red). In particular Akt-1 was identified in
both analyses. This finding suggested the possibility that IL-4
induction of miR-378-3p results in a negative feedback on the IL-4
signaling pathway. Because receptor “tolerance” has not previously
been described for this pathway, we tested whether IL-4 does
induce a negative feedback-mechanism by measuring STAT-6–
phosphorylation in Thio-M after secondary IL-4 stimulation. As
outlined in Figure 3B, M that had previously been exposed to
IL-4 showed reduced and delayed STAT-6 phosphorylation in
response to secondary IL-4 stimulation.
To obtain direct evidence that miR-378-3p targets the PI3K/Akt1-
pathway, we generated Luciferase-constructs containing the 3UTR
of thymoma viral proto-oncogene 1 (Akt1) or a mutated version
thereof where 2 nucleotides within both seed-region-binding sites
for miR-378-3p were altered (supplemental Figure 1A). As shown
in Figure 3C, cotransfecting NIH-3T3 fibroblasts with a mimic of
miR-378-3p significantly inhibited Luciferase expression com-
pared with cells transfected with the Luciferase construct alone or
cotransfected with a negative control RNA. Importantly, these
effects were lost when both miR-378-3p–binding sites within the
Akt1-3UTR were mutated. Furthermore, transfection of RAW264.7
cells led to a marked decrease in Akt-1 protein levels as assessed by
Western blot analysis (P  .01 in every comparison; Figure 3D-E).
Similar results were obtained for growth factor receptor–bound
protein 2 (Grb2; P .05; supplemental Figure 1B-D). Interestingly, the
use of a miR-378-3p inhibitor increased protein expression of Akt-1 in
some experiments, but this was not significant when the data of several
experiments were combined (Figure 3D-E).
The identification of Akt as a target of miR-378-3p led us to
assess the potential influence of Akt-inhibition on M alternative
activation by using a specific Akt inhibitor, triciribine30 (Figure 4).
Preincubation of Thio-M with triciribine severely disrupted their
ability to fully alternatively activate in a dose-dependent manner as
shown for the expression of Chi3l3, resistin-like  (Retnla/Relm-)
and arginase 1 (Arg1; Figure 4). Of note, Akt inhibition differen-
tially affected the expression of these markers with complete
abrogation of IL-4–driven Retnla but only partial inhibition of
Chi3l3 and Arg1 induction. In contrast, other marker genes of
alternative M activation (eg, Cd36, Pparg, Ppargc1b) were not
negatively influenced by the inhibition of Akt. Thus, limiting
Akt-signaling does not completely block IL-4–mediated alternative
activation but changes the associated gene expression profile,
perhaps to generate cells better suited to chronic type-2 inflamma-
tory settings.
We recently demonstrated that proliferation of the local M
population is an integral part of Th2-mediated inflammation with
no requirement for blood monocyte recruitment.20 The expansion
in cell numbers after surgical implantation of B malayi nematodes
occurs as an early burst of rapid cellular proliferation, which then
Figure 3. miR-378-3p targets the IL-4R/PI3K/Akt-signaling pathway. (A) Schematic depiction of the IL-4R–signaling cascade highlighting putative targets for miR-378-3p.
Yellow indicates predicted by TargetScan; red: differentially expressed genes in pre- and anti-miR-378-3p–transfected fibroblasts. (B) Analysis of rIL-4–elicited STAT-6
phosphorylation by intracellular FACS staining. Histogram of STAT-6 (pY641) expression in Thio-M preincubated with rIL-4 (orange line) or medium (red line) for 24 hours
before restimulation with rIL-4 (open histograms) or medium (filled gray histograms) for 5 minutes. Timeline of pSTAT-6 (pY641) expression in rIL-4 (orange squares) or
medium (red circles) pretreated, rIL-4–stimulated (colored symbols) or unstimulated (gray symbols) cells. Data show median fluorescence intensity of 6 individual
animals SEM. For unstimulated controls, cells were pooled from several animals. Asterisks indicate statistical differences between rIL-4–preincubated and freshly stimulated
M. ***P  .001; **P  .01. (C) Luciferase-assay using the 3UTR of wild-type Akt-1 (Akt-1) or constructs with mutated seed-region binding sites for both predicted
miR-378-3p binding sites (mut) or without insert (empty). Data indicate cotransfection with a miR-378-3p mimic (black bars) or a scrambled control (open bars). Data are pooled
from 5 separate experiments and depicted as relative luminescence compared with no-RNA controls (gray bars). Bars not connected by the same letters are statistically
significantly different. (D) Representative Western blot analysis of RAW264.7 cells 12 hours after transfection with a mimic (pre-378) or inhibitor (anti-378) of miR-378-3p or
appropriate negative controls (pre- and anti-neg). Samples were separated on 4%-12% Bis-Tris gels and stained for Akt-1 and 	-actin at the same time. (E) Densitometric
analysis of the samples analyzed in panel D. Data are representative of 4 separate experiments. Columns not connected by the same letters are statistically significantly
different.
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subsides (supplemental Figure 4 in Jenkins et al20). Of note, RNA
isolated from these M revealed a delayed increase in miR-378-3p
expression that peaked when M proliferation subsided and Akt1
gene expression declined (Figure 5). Critically, injection of active
IL-4 alone can drive this proliferative program in vivo. Because
both miRNAs and the PI3K/Akt pathway inherently are associated
with cellular growth and proliferation, we speculated that IL-4–
driven M proliferation is mediated via Akt signaling, with
miR-378-3p and possibly other miRNAs acting as negative
regulators.
We thus chose to test the role of Akt-signaling during IL-4–
mediated M proliferation. For this, mice received a single dose of
Figure 4. Akt-inhibition modulates alternative activa-
tion of M in vitro. Thio-M were stimulated with rIL-4
() or medium () after preincubation with the indicated
concentration of triciribine for 1 hour and analyzed for
expression of alternative activation markers by qRT-
PCR. Data are representative of 3-4 animals per group.
Error bars indicate SEM. One of 4 experiments shown.
Asterisks indicate statistical differences compared with
IL-4–treated samples. ***P  .001, **P  .01.
Figure 5. Time course of miR-378-3p expression and
markers of proliferation after B malayi implantation.
(A) Gene expression of miR-378-3p and Akt1 in perito-
neal M isolated from B malayi implanted C57BL/6 mice
at the indicated time points after implantation. N indicates
naive animals. Data points represent individual animals
or separate pools of animals. (B) FACS analysis of Ki67
expression and BrdU incorporation in the M analyzed in
panel A. Data from the same experiment shown in
supplemental Figure 4 in Jenkins et al.20 One experiment
of 1 shown. ***P  .001; **P  .01; *P  .05.
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triciribine or vehicle control intraperitoneally 1 hour before the
injection of IL-4 complexed with anti–IL-4 antibody (IL-4c), which
allows sustained delivery of active cytokine.20 After 21 hours, mice
were injected with BrdU to label cells in the S-phase, and 3 hours
later peritoneal exudate cells were analyzed for expression of
proliferation and alternative activation markers by FACS. Pretreat-
ment with triciribine completely abrogated IL-4c–induced M
proliferation as measured by the incorporation of BrdU or expres-
sion of Ki67 (Figure 6A). Simultaneously, protein levels of the
alternative activation marker Relm- were only partially reduced
and YM-1 expression did not seem affected at all. These data
indicate that similar to the effects observed in vitro, IL-4–induced
Akt-signaling is responsible for only specific features of alternative
M activation but is essential for IL-4–driven proliferation.
Furthermore, to establish a role for miR-378-3p in the regula-
tion of M proliferation,we transfected RAW264.7 cells with a
miR-378-3p mimic or inhibitor and analyzed the resulting changes
in cellular expansion. Conversion of alamarBlue and loss of
Vybrant CFDA SE staining were used to monitor cell expansion
and cell division, respectively. During a 24-hour period, cells
transfected with the miR-378-3p mimic displayed a significantly
reduced increase in the conversion of alamarBlue (Figure 6B) and
loss of Vybrant CFDA SE staining (Figure 6C), demonstrating that
miR378-3p negatively regulated cell proliferation. Transfection
with the miR-378-3p inhibitor had no effect on cellular expansion,
indicating that only enhanced miR-378-3p expression as found
after IL-4 stimulation regulates proliferation. What is more,
gene-expression analyses of RAW264.7 cells transfected with
miR-378-3p showed significant reduction in expression of Akt-1
and Grb2, as well as the putative target Pik3cb (Figure 3A) and the
proliferation marker Mki67 (Figure 6D). Taken together, these
results are consistent with a negative regulation of M prolifera-
tion by miR-378-3p through modulation of the PI3K/Akt-signaling
pathway.
IL-4 impacts the activation state of many cell types, and the
PI3K/Akt pathway regulates cellular expansion in various biologic
settings. Thus, to determine whether induction of miR-378-3p and
therefore potential regulation of PI3K/Akt signaling was a general
characteristic of either M proliferation or IL-4 signaling in other
cell types, we analyzed miR-378-3p expression in M during
IL-4–independent, M-CSF–driven proliferation and in B and
T cells after IL-4c stimulation in vivo. As expected, treatment of
Thio-M with rM-CSF in vitro stimulated M proliferation as
confirmed by increased gene expression of Mki67 (Figure 7A).
However, at no point after stimulation could the induction of
miR-378-3p or its parent gene (Ppargc1b) be detected.
Similarly, enhanced expression of miR-378-3p and Ppargc1b
after IL-4c injection in vivo was found in peritoneal M (F4/
80CD11b) but not in B cells (CD19F4/80), CD4
(CD4CD11b), or CD8 lymphocytes (CD8CD11b) isolated
Figure 6. Akt inhibition and miR-378-3p overexpres-
sion negatively regulate M proliferation. (A) BALB/c
mice were injected intraperitoneally with a single dose of
triciribine (1 mg/kg) or vehicle control 1 hour before
injection of IL-4c or PBS. After 24 hours cells were
analyzed for proliferation and alternative activation by
FACS analysis. Each data point is representative of an
individual animal. Pooled data from 3 separate experi-
ments shown. (B) Conversion of alamarBlue by
RAW264.7 cells 24 and 48 hours after transfection with a
miR-378-3p mimic (black squares) or inhibitor (black
circles) or the appropriate negative controls (open sym-
bols). Data representative of 3 separate experiments.
(C) FACS-analysis of Vybrant CFDA SE dilution in the
cells analyzed in panel A. (D) Gene expression of
miR-378-3p target genes and genes associated with cell
proliferation in RAW264.7 cells 48 hours after transfec-
tion with a miR-378-3p mimic (black bars) or the appropri-
ate negative control (open bars). ***P  .001; **P  .01;
*P  .05; n.s. indicates not significant.
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from the same animal (Figure 7B). Of note, IL-4c has previously
been shown to also induce proliferation of CD8 lymphocytes,31 as
confirmed in our data by increased expression of cyclin A2
(Ccna2). The failure to induce miR-378-3p in these cells as well as
in M-CSF–stimulated macrophages indicates that miR-378-3p is
not a general feature of cellular proliferation, whether IL-4
dependent or independent. Furthermore, the lack of induction of
miR-378-3p in other cells stimulated with IL-4c shows that
although IL-4 signaling has widespread effects on various cell
types, the mechanisms controlling these effects are governed by
different regulatory mechanisms. Induction of miR-378-3p there-
fore appears to be a very specific feature of alternative M
activation.
Discussion
M isolated from mice infected with the human filarial parasite
B malayi become alternatively activated because of exposure to
Th2 cells.21 In this in vivo setting, we have identified changes in
M expression of miR-125b-5p, miR-199b-5p, miR-378-3p, and
miR-146a-5p associated with IL-4R–driven alternative activa-
tion. In vitro confirmation revealed that miR-125b-5p, miR-378-
3p, and miR-146a-5p were directly regulated by IL-4, whereas
miR-199b-5p was not, suggesting miR-199b-5p is induced in vivo
by other factors and/or that IL-4 is not sufficient. Interestingly
another miRNA, miR-223-3p, has recently been described to be
associated with the alternative activation phenotype.32 Indeed,
miR-223-3p was significantly enhanced in WT NeM vs IL-
4R/ NeM in our array but was not among the most highly
differentially expressed microRNAs in this in vivo setting and thus
not pursued in this study.
Both miR-125b-5p and miR-146a-5p have already been associ-
ated with classical M activation. miR-125b-5p expression is
initially reduced after LPS stimulation, allowing efficient produc-
tion of its target, the proinflammatory cytokine TNF-15 but
miR-125b-5p is then up-regulated during LPS-tolerance to prevent
further/excessive TNF production.16 Thus, miR-125b-5p up-
regulation in alternatively activated M may represent a failsafe
switch preventing concomitant production of proinflammatory
mediators like TNF-. miR-146a-5p, on the other hand, is normally
induced after classical activation of monocytes and is presumed to
act in a feedback loop, blocking further TLR and cytokine
signaling.17,33 Downmodulation of this miRNA in IL-4–stimulated
M could enhance TLR signaling and thus seems counterintuitive.
However, reduced levels of miR-146a-5p did not occur until very
late after IL-4 stimulation (Figure 3), and long-term preincubation
of M with IL-4 has previously been shown to potentiate
production of proinflammatory cytokines after secondary stimula-
tion with LPS.34 Thus, whereas up-regulation of miR-125b-5p
might help prevent concomitant production of inflammatory media-
tors, miR-146a-5p–downmodulation may simultaneously sensitize
M for potential bacterial pathogens and allow M to quickly
adapt their activation phenotype to newly arising challenges.
Further experiments are needed to determine the exact role of these
2 miRNAs in shaping M activation.
Here we focus on the new finding that up-regulation of
miR-378-3p is part of the alternative M activation program. This
finding is consistent with a report that miR-378-3p is up-regulated
in a model of allergic airway inflammation.35 Although the authors
did not perform cell-type specific analyses, the inflammatory
response in these models is characterized by the accumulation of
M exhibiting an alternative activation phenotype.36 As noted
previously, miR-378-3p is encoded in an intronic region of
Ppargc1b,26 a protein associated with alternative activation.27
Thus, coexpression of miR-378-3p may have evolved to comple-
ment the role of the protein-encoding gene.37 Ppargc1b is ex-
pressed by 4 hours after IL-4 stimulation, which would suggest that
Ppargc1b and the primary transcript of mir-378-3p are primary
targets of IL-4–induced gene transcription. However, the mature
form of miR-378-3p is delayed with respect to its parent gene and
Figure 7. Induction of miR-378-3p is specific to IL-4–mediated signaling in M.
(A) Thio-elicited, adherence-purified M were incubated with rIL-4 (black squares),
rM-CSF (gray circles), or with medium alone (open squares) for the indicated time
and analyzed for miRNA and mRNA expression. Statistics indicate differences
between rM-CSF–treated samples and rIL-4 controls. ***P  .001. Each data point
represents mean and SEM of 6 individual animals. Results from a single experiment
shown. (B) CD11bF4/80 (M), CD19F4/80 (B cells), CD4CD11b lympho-
cytes (CD4) and CD8CD11b lymphocytes (CD8) were FACS-sorted from IL-4c
injected (filled bars) or PBS-injected control animals (open bars) and subjected to
qRT-PCR. Data are depicted as fold change above PBS controls. Statistics indicate
differences between IL-4c–treated samples and PBS-controls. ***P  .001; *P  .05.
Bars depict mean and SEM of 10 individual animals per group pooled from
2 independent experiments, except for the CD8 data, which is from 1 representative
experiment. The second experiment is not shown because Ccna2 in the PBS controls
was not detectable resulting in a fold change of infinity for the IL-4c treatment.
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other alternative activation markers and thus secondary factors may
be needed to regulate its processing.
We identified several miR-378-3p targets within the IL-4R–
signaling cascade and more specifically within the PI3K/Akt-
signaling pathway. Previous work by MacKinnon et al showed that
signaling via PI3K is important for full alternative activation of
M,38 and we have extended these findings by using the Akt-
specific inhibitor triciribine, confirming Akt as an important
downstream target of PI3K during IL-4–induced alternative activa-
tion. Interestingly Varin et al showed that pretreatment of M with
IL-4 prevented subsequent Akt signaling induced by Neisseria
meningitidis, suggesting the induction of a feedback inhibitory
mechanism by IL-4.39 Importantly these effects were not observed
until approximately 12 hours after IL-4 stimulation, a time point
that roughly coincides with the induction of miR-378-3p in our
experiments. In addition miR-378-3p has been predicted to target
the progesterone-receptor,40 and progesterone has been shown to be
an important enhancement factor for alternative activation in
wound healing.41 Taken together, these findings strongly suggest a
role for miR-378-3p as feedback inhibitor of alternative activation.
In this context PI3K/Akt signaling has been shown to enhance
antiinflammatory cytokine production during classical M activa-
tion and simultaneously reduce production of proinflammatory
cytokines.42 Thus, induction of miR-378-3p and limitation of
Akt-signaling in alternatively activated M could, similar to our
findings with miR-146a-3p, indicate a sensitization for potential
concomitant bacterial infections.
PI3K/Akt is a central signaling pathway important for cellular
growth and survival, triggered by various growth factors and
insulin but also by cytokines and TLR stimulation.43 Although
tissue M typically have been regarded as nondividing, recent data
show that resident M numbers can be maintained by prolifera-
tion.20,44,45 We further demonstrated that tissue M can undergo
rapid and extensive proliferation in vivo in response to IL-4 as a
mechanism of Th2-driven inflammation that can replace monocyte
recruitment.20 Using triciribine, we show here that, similar to the
findings in vitro, intact PI3K/Akt-signaling enhances alternative
activation of M in vivo but moreover is absolutely essential for
IL-4–induced M proliferation.
In a related context, miR-378-3p has been shown to be
up-regulated during differentiation of proliferating myoblasts to
nonproliferating myotubes and consequently severely downmodu-
lated in cardiotoxin-induced muscle regeneration.46 Similarly, in a
model of surgically induced liver injury downmodulation of
miR-378-3p has been proposed to allow efficient hepatocyte
proliferation by derepressing pro-proliferative molecules like orni-
thine decarboxylase.47 A human ortholog of miR-378-3p with
identical mature sequence, miR-422a, has, in concert with other
miRNAs, been proposed to block proliferation of tumor cells by
targeting the MAPK pathway.48 Taken together with our observa-
tion that miR-378-3p negatively regulated RAW264.7 cell expan-
sion, these results suggest that miR-378-3p is centrally involved in
the control of proliferation. Indeed, some of the main pathways
identified as potential targets for miR-378-3p in our bioinformatic
pathway analysis of transfected fibroblasts, in addition to the
Jak/Stat-signaling pathway, included cell cycle–, p53-, and MAPK-
signaling pathways, which merit further validation. Importantly our
data indicate that despite miR-378-3p having the potential to
control proliferation in various cell types and under multiple
settings, its induction under normal conditions seems restricted to
IL-4–activated M. Most likely this reflects the fact that miR-
378-3p will target other, as yet-undefined target genes besides Akt1
and thus have a much broader effect on the cellular phenotype, than
discussed here.
We have been unable to demonstrate significant M prolifera-
tion with IL-4 in vitro, suggesting that additional signals to the cell,
either through cell–cell contacts or as yet-undefined soluble
mediators are required. In addition, miRNAs do not typically
induce complete knockdown of their targets,12 and miRNAs often
act in families targeting a whole metabolic or signaling pathway
rather than individual members of these pathways leading to a
general suppression of whole metabolic or activation program.49
Further, in vivo M transfection with miRNAs is challenging. For
these reasons, it remains to be directly demonstrated whether
miR-378-3p, possibly in combination with other miRNAs, regu-
lates M proliferation via Akt inhibition in vivo. We have
circumstantial evidence showing that peak proliferation of M
after B malayi implantation precedes miR-378-3p induction and
this is paralleled by a concomitant down-regulation in Akt1-
expression (Figure 5). Similarly transfection of RAW264.7 cells
with miR-378-3p reduced expression of PI3K/Akt-pathway mol-
ecules and negatively impacted on cellular expansion.
Beyond the putative link between miR-378-3p and IL-4–driven
macrophage proliferation, this study has generated the novel and
important finding that miR-378-3p is an IL-4–dependent miRNA
up-regulated in M both in vitro and in vivo, which targets the
Akt-signaling pathway. Importantly, this finding has led to the
independent observation that the local M proliferation that occurs
during Th2 mediated inflammation relies on Akt. This has impor-
tant therapeutic implications as PI3K/Akt inhibitors are already
being developed to target proliferation during cancer50,51 and thus
might have off target effects on M. In addition, efforts to target
this pathway may generate important therapeutics to control M
proliferation, which is believed to exacerbate diseases such as
glomerulonephritis and atherosclerosis.52,53
Acknowledgments
The authors thank Yvonne Harcus for excellent technical assis-
tance, Martin Waterfall for performing outstanding FACS sorting,
and Frank Brombacher for providing the IL-4R/ mice.
This work was funded by the Medical Research Council United
Kingdom (MRC-UK G0600818) and the Wellcome Trust (Center
for Immunity, Infection and Evolution; 082611/Z/07/Z). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Authorship
Contribution: D.R. designed and performed research, analyzed and
interpreted data, and wrote the manuscript; S.J.J. performed
research, analyzed and interpreted data, and contributed vital new
analytical tools; N.N.L. performed research, analyzed and inter-
preted data; I.J.G. analyzed and interpreted data; T.E.S. contributed
vital new tools; S.D. performed research; and A.H.B. and J.E.A.
contributed to data interpretation, manuscript preparation, and
project supervision.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
MICRORNAS AND CONTROL OF PROLIFERATION IN AAM 2315BLOOD, 13 SEPTEMBER 2012  VOLUME 120, NUMBER 11
 personal use only.
For at ROYAL SCHOOL OF VETERINARY STUDIES on July 11, 2013. bloodjournal.hematologylibrary.orgFrom 
Correspondence: Judith E. Allen, The University of Edinburgh,
Institute of Immunology and Infection Research, Ashworth Labora-
tories, West Mains Rd, EH9 3JT Edinburgh, United Kingdom;
e-mail: j.allen@ed.ac.uk.
References
1. Gordon S. Alternative activation of macrophages.
Nat Rev Immunol. 2003;3(1):23-35.
2. Biswas SK, Mantovani A. Macrophage plasticity
and interaction with lymphocyte subsets: cancer
as a paradigm. Nat Immunol. 2010;11(10):889-
896.
3. Díaz A, Allen JE. Mapping immune response pro-
files: the emerging scenario from helminth immu-
nology. Eur J Immunol. 2007;37(12):3319-3326.
4. Gordon S, Martinez FO. Alternative activation of
macrophages: mechanism and functions. Immu-
nity. 2010;32(5):593-604.
5. Loke P, Nair MG, Parkinson J, Guiliano D,
Blaxter M, Allen JE. IL-4 dependent alternatively-
activated macrophages have a distinctive in vivo
gene expression phenotype. BMC Immunol.
2002;3:7.
6. Martinez FO, Sica A, Mantovani A, Locati M. Mac-
rophage activation and polarization. Front Biosci.
2008;13:453-461.
7. Murray PJ, Wynn TA. Obstacles and opportuni-
ties for understanding macrophage polarization.
J Leukoc Biol. 2011;89(4):557-563.
8. Ho¨lscher C, Ho¨lscher A, Ru¨ckerl D, et al. The
IL-27 receptor chain WSX-1 differentially regu-
lates antibacterial immunity and survival during
experimental tuberculosis. J Immunol. 2005;
174(6):3534-3544.
9. Lang R, Patel D, Morris JJ, Rutschman RL,
Murray PJ. Shaping gene expression in activated
and resting primary macrophages by IL-10. J Im-
munol. 2002;169(5):2253-2263.
10. Rhen T, Cidlowski JA. Antiinflammatory action of
glucocorticoids—new mechanisms for old drugs.
N Engl J Med. 2005;353(16):1711-1723.
11. Ivashkiv LB. Inflammatory signaling in macro-
phages: transitions from acute to tolerant and al-
ternative activation states. Eur J Immunol. 2011;
41(9):2477-2481.
12. Guo H, Ingolia NT, Weissman JS, Bartel DP.
Mammalian microRNAs predominantly act to de-
crease target mRNA levels. Nature. 2010;
466(7308):835-840.
13. O’Neill LA, Sheedy FJ, McCoy CE. MicroRNAs:
the fine-tuners of Toll-like receptor signalling. Nat
Rev Immunol. 2011;11(3):163-175.
14. Androulidaki A, Iliopoulos D, Arranz A, et al. The
kinase Akt1 controls macrophage response to
lipopolysaccharide by regulating microRNAs. Im-
munity. 2009;31(2):220-231.
15. Tili E, Michaille J-J, Cimino A, et al. Modulation of
miR-155 and miR-125b levels following
lipopolysaccharide/TNF-alpha stimulation and
their possible roles in regulating the response to
endotoxin shock. J Immunol. 2007;179(8):5082-
5089.
16. El Gazzar M, McCall CE. MicroRNAs distinguish
translational from transcriptional silencing during
endotoxin tolerance. J Biol Chem. 2010;285(27):
20940-20951.
17. Taganov KD, Boldin MP, Chang K-J, Baltimore D.
NF-kappaB–dependent induction of microRNA
miR-146, an inhibitor targeted to signaling pro-
teins of innate immune responses. Proc Natl
Acad Sci U S A. 2006;103(33):12481-12486.
18. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T.
The interleukin 13 (IL-13) pathway in human mac-
rophages is modulated by microRNA-155 via di-
rect targeting of interleukin 13 receptor alpha1
(IL13R{alpha}1). J Biol Chem. 2010;286(3):1786-
1794.
19. Palma CA, Tonna EJ, Ma DF, Lutherborrow MA.
MicroRNA control of myelopoiesis and the differ-
entiation block in acute myeloid leukaemia. J Cell
Mol Med. 2012;16(5):978-987.
20. Jenkins SJ, Ruckerl D, Cook PC, et al. Local
macrophage proliferation, rather than recruitment
from the blood, is a signature of TH2 inflamma-
tion. Science. 2011;332(6035):1284-1288.
21. Loke P, Gallagher I, Nair MG, et al. Alternative
activation is an innate response to injury that re-
quires CD4 T cells to be sustained during
chronic infection. J Immunol. 2007;179(6):3926-
3936.
22. Smyth GK. Limma: linear models for microarray
data. In: Gentleman R, Carey V, Huber W,
Irizarry R, Dudoit S, eds. Bioinformatics and
Computational Biology Solutions using R and
Bioconductor. New York: Springer; 2005:397-420.
23. Gentleman RC, Carey VJ, Bates DM, et al. Bio-
conductor: open software development for com-
putational biology and bioinformatics. Genome
Biol. 2004;5(10):R80.
24. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A
comparison of normalization methods for high
density oligonucleotide array data based on vari-
ance and bias. Bioinformatics. 2003;19(2):185-
193.
25. Whyte CS, Bishop ET, Ruckerl D, et al. Suppres-
sor of cytokine signaling (SOCS)1 is a key deter-
minant of differential macrophage activation and
function. J Leukoc Biol. 2011;90(5):845-854.
26. Eichner LJ, Perry MC, Dufour CR, et al. miR-
378(*) mediates metabolic shift in breast cancer
cells via the PGC-1beta/ERRgamma transcrip-
tional pathway. Cell Metab. 2010;12(4):352-361.
27. Vats D, Mukundan L, Odegaard JI, et al. Oxida-
tive metabolism and PGC-1beta attenuate
macrophage-mediated inflammation. Cell Metab.
2006;4(1):13-24.
28. Mosser DM. The many faces of macrophage acti-
vation. J Leukoc Biol. 2003;73(2):209-212.
29. Santhakumar D, Forster T, Laqtom NN, et al.
Combined agonist-antagonist genome-wide func-
tional screening identifies broadly active antiviral
microRNAs. Proc Natl Acad Sci U S A. 2010;
107(31):13830-13835.
30. Sun J, Ramnath RD, Tamizhselvi R, Bhatia M.
Role of protein kinase C and phosphoinositide
3-kinase-Akt in substance P-induced proinflam-
matory pathways in mouse macrophages.
FASEB J. 2009;23(4):997-1010.
31. Boyman O, Kovar M, Rubinstein MP, Surh CD,
Sprent J. Selective stimulation of T cell subsets
with antibody-cytokine immune complexes. Sci-
ence. 2006;311(5769):1924-1927.
32. Zhuang G, Meng C, Guo X, et al. A novel regula-
tor of macrophage activation: miR-223 in obesity
associated adipose tissue inflammation. Circula-
tion. 2012;125(23):2892-2903.
33. Jurkin J, Schichl YM, Koeffel R, et al. miR-146a is
differentially expressed by myeloid dendritic cell
subsets and desensitizes cells to TLR2-dependent
activation. J Immunol. 2010;184(9):4955-4965.
34. D’Andrea A, Ma X, Aste-Amezaga M, Paganin C,
Trinchieri G. Stimulatory and inhibitory effects of
interleukin (IL)-4 and IL-13 on the production of
cytokines by human peripheral blood mononu-
clear cells: priming for IL-12 and tumor necrosis
factor alpha production. J Exp Med. 1995;181(2):
537-546.
35. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21
is up-regulated in allergic airway inflammation
and regulates IL-12p35 expression. J Immunol.
2009;182(8):4994-5002.
36. Melgert BN, Oriss TB, Qi Z, et al. Macrophages:
regulators of sex differences in asthma? Am J
Respir Cell Mol Biol. 2010;42(5):595-603.
37. van Rooij E, Quiat D, Johnson BA, et al. A family
of microRNAs encoded by myosin genes governs
myosin expression and muscle performance. Dev
Cell. 2009;17(5):662-673.
38. MacKinnon A, Farnworth S, Hodkinson P, et al.
Regulation of alternative macrophage activation
by galectin-3. J Immunol. 2008;180(4):2650-
2658.
39. Varin A, Mukhopadhyay S, Herbein G, Gordon S.
Alternative activation of macrophages by IL-4 im-
pairs phagocytosis of pathogens but potentiates
microbial-induced signalling and cytokine secre-
tion. Blood. 2010;115(2):353-362.
40. Zhou J, Song T, Gong S, Zhong M, Su G. mi-
croRNA regulation of the expression of the estro-
gen receptor in endometrial cancer. Mol Med
Rep. 2010;3(3):387-392.
41. Routley CE, Ashcroft GS. Effect of estrogen and
progesterone on macrophage activation during
wound healing. Wound Repair Regen. 2009;
17(1):42-50.
42. Martin M, Rehani K, Jope RS, Michalek SM. Toll-
like receptor-mediated cytokine production is dif-
ferentially regulated by glycogen synthase kinase
3. Nat Immunol. 2005;6(8):777-784.
43. Weichhart T, Saemann MD. The PI3K/Akt/mTOR
pathway in innate immune cells: emerging thera-
peutic applications. Ann Rheum Dis. 2008;
67(Suppl 3):iii70-iii74.
44. Chorro L, Sarde A, Li M, et al. Langerhans cell
(LC) proliferation mediates neonatal develop-
ment, homeostasis, and inflammation-associated
expansion of the epidermal LC network. J Exp
Med. 2009;206(13):3089-3100.
45. Davies LC, Rosas M, Smith PJ, Fraser DJ,
Jones SA, Taylor PR. A quantifiable proliferative
burst of tissue macrophages restores homeo-
static macrophage populations after acute inflam-
mation. Eur J Immunol. 2011;41(8):2155-2164.
46. Gagan J, Dey BK, Layer R, Yan Z, Dutta A.
MICRORNA-378 targets the myogenic repressor
MyoR during myoblast differentiation. J Biol
Chem. 2011;286:19431-19438.
47. Song G, Sharma AD, Roll GR, et al. MicroRNAs
control hepatocyte proliferation during liver re-
generation. Hepatology. 2010;51(5):1735-1743.
48. Gougelet A, Pissaloux D, Besse A, et al. Micro-
RNA profiles in osteosarcoma as a predictive tool
for ifosfamide response. Int J Cancer. 2011;
129(3):680-690.
49. Xiao C, Rajewsky K. MicroRNA control in the im-
mune system: basic principles. Cell. 2009;136(1):
26-36.
50. Cheng JQ, Lindsley CW, Cheng GZ, Yang H,
Nicosia SV. The Akt/PKB pathway: molecular tar-
get for cancer drug discovery. Oncogene. 2005;
24(50):7482-7492.
51. Sarker D, Reid AHM, Yap TA, de Bono JS. Target-
ing the PI3K/AKT pathway for the treatment of
prostate cancer. Clin Cancer Res. 2009;15(15):
4799-4805.
52. Isbel NM, Nikolic-Paterson DJ, Hill PA, Dowling J,
Atkins RC. Local macrophage proliferation corre-
lates with increased renal M-CSF expression in
human glomerulonephritis. Nephrol Dial Trans-
plant. 2001;16(8):1638-1647.
53. Kuo CL, Murphy AJ, Sayers S, et al. Cdkn2a is an
atherosclerosis modifier locus that regulates
monocyte/macrophage proliferation. Arterioscler
Thromb Vasc Biol. 2011;31(11):2483-2492.
2316 RU¨ CKERL et al BLOOD, 13 SEPTEMBER 2012  VOLUME 120, NUMBER 11
 personal use only.
For at ROYAL SCHOOL OF VETERINARY STUDIES on July 11, 2013. bloodjournal.hematologylibrary.orgFrom 
